You guys can take this for what it's worth, but I just got off the phone with ITOR/GHS, where the trials are being conducted. Here its the gist of my phone call with them:
I had asked why the trials had stopped, and was told that it was due to Prolanta being in short supply. They had a lot more than 3 patients enrolled and tested on, but were only able to complete 3, because of the supply shortage. The woman on the phone told me that every single patient had tolerated the drug well with little to no side effects. I asked her about the efficacy of the drug, and she told me that every patient that was tested had progressed with their conditions and it's a shame that they had to stop the trials.
As you know, the trials were last updated back in April and that is also around the time that Oncolix had decided to go public. So if you put two and two together, they are obviously doing this in order to continue funding their trials and manufacturing of Prolanta.
All in all, I would say it was a positive phone call and is in line with a lot of what we already knew. It sure made me feel good to hear her say that ALL of the patients were progressing.
